Literature DB >> 8126140

Reduced bone mineral density in patients with adult onset growth hormone deficiency.

S J Holmes1, G Economou, R W Whitehouse, J E Adams, S M Shalet.   

Abstract

We have demonstrated previously that adults with isolated GH deficiency of childhood onset have a reduced bone mineral density (BMD) of vertebral trabecular bone [quantitative computed tomography (QCT): median Z score -1.3, P < 0.01, n = 12] and of cortical bone in the forearm [single photon absorptiometry (SPA): median Z score -2.9, P = 0.001, n = 7]. We have now examined BMD in 26 patients (13 men, 13 women), aged between 23.6 and 59.5 (mean 42.4) yr, with adult onset GH deficiency, defined as a GH response of less than 5 micrograms/L to provocative testing, of at least two years duration. BMD was measured using QCT for vertebral trabecular bone, dual energy x-ray absorptiometry (DXA) in the lumbar spine and femoral neck, and SPA in the forearm. There was a highly significant reduction in QCT (median Z score -1.07, P < 0.00005), in DXA of the lumbar spine (median Z score -0.76, P = 0.0001) and in SPA of the forearm (median Z score -0.86, P = 0.0001) but not in DXA of the femoral neck (median Z score -0.38, P = 0.35). There were no significant differences in Z scores between those patients with isolated GH deficiency and those with GH and gonadotrophin deficiency. There was a significant positive correlation between age at which BMD was measured and Z score (the older the patient, the higher the Z score) for QCT (r = 0.38, P < 0.05) and SPA (r = 0.48, P < 0.01) with a trend to a positive correlation for DXA of the lumbar spine and femoral neck. Patients were grouped according to estimated duration of GH deficiency (less than 5 yr, n = 7; 5-10 yr, n = 10; greater than 10 yr, n = 9). These groups did not show a significant difference in BMD at any site. We conclude that patients with adult onset GH deficiency (isolated or in conjunction with other pituitary hormone deficiencies) have a reduced BMD. Age at development of GH deficiency may be more important than duration of GH deficiency in determining the degree of reduction in bone mass. The impact of GH treatment on BMD in adults with adult onset GH deficiency requires investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126140     DOI: 10.1210/jcem.78.3.8126140

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  43 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Prevalence of osteopenia in men with prolactinoma.

Authors:  E C O Naliato; M L F Farias; G R Braucks; F S R Costa; D Zylberberg; A H D Violante
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 4.  Skeletal effects of growth hormone and IGF-I in adults.

Authors:  R Marcus
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

5.  Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency.

Authors:  A Sartorio; S Ortolani; A Conti; R Cherubini; E Galbiati; G Faglia
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

Review 6.  The Gordon Wilson Lecture. Growth hormone replacement in adults and other uses.

Authors:  M L Vance
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

7.  Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems!

Authors:  Maria Fleseriu
Journal:  Endocrine       Date:  2018-01-19       Impact factor: 3.633

8.  Bone mineral density in survivors of childhood brain tumours.

Authors:  M Petraroli; E D'Alessio; E Ausili; A Barini; P Caradonna; R Riccardi; M Caldarelli; A Rossodivita
Journal:  Childs Nerv Syst       Date:  2006-10-13       Impact factor: 1.475

9.  Evidence that sensitivity to growth hormone (GH) is growth period and tissue type dependent: studies in GH-deficient lit/lit mice.

Authors:  Yuji Kasukawa; David J Baylink; Rongqing Guo; Subburaman Mohan
Journal:  Endocrinology       Date:  2003-09       Impact factor: 4.736

10.  Effects of gender, body weight, and blood glucose dynamics on the growth hormone response to the glucagon stimulation test in patients with pituitary disease.

Authors:  Jessica R Wilson; Andrea L Utz; Jessica K Devin
Journal:  Growth Horm IGF Res       Date:  2015-12-08       Impact factor: 2.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.